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Abstract
The human malaria parasite Plasmodium vivax imposes unique challenges to its control 
and elimination. Primary among those is the hypnozoite reservoir of infection in endemic 
communities. It is the dominant source of incident malaria and exceedingly difficult to 
attack due to both inability to diagnose latent carriers and the potentially life-threatening 
toxicity of primaquine in patients with an inborn deficiency of G6PD, the only therapeu-
tic option against hypnozoites. Large segments of endemic populations are not eligible 
for primaquine, and alternative strategies for managing the threat of relapse in any group 
have not been optimized or validated. Association of risk of primaquine failure against 
latent P. vivax with impaired alleles of P450 2D6 exacerbates the substantial pool of pri-
maquine ineligibles. Resistance to chloroquine against acute P. vivax malaria commonly 
occurs; alternative therapies like ACTs are effective but seldom evaluated as a partner 
drug to primaquine in the essential radical cure. Many of the Anopheles mosquito vector 
of P. vivax in South and Southeast Asia, where >90% of infections occur, thrive in a diver-
sity of habitats and exhibit wide ranges of feeding and breeding behavior. This chapter 
explores many of these challenges and possible approaches in controlling and eliminat-
ing endemic vivax malaria.
Keywords: Plasmodium vivax, malaria, latent malaria, hypnozoites, glucose-6-phosphtate 
dehydrogenase (G6PD), Anopheles mosquitoes, species-sanitation, control
1. Introduction
Human malaria caused by Plasmodium vivax currently has the widest geographical distri-
bution among all malaria parasites with about 35% of the world population living at risk 
of this physically debilitating and sometime lethal infection [1–3]. Figure 1 illustrates this 
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global distribution most heavily weighing upon South and Southeast Asia (SEA) [1]. In most 
endemic countries, chloroquine (CQ) remains the first-line therapy for acute vivax malaria 
after more than 70 years of continuous use. CQ-resistant P. vivax, documented nearly 
30 years ago, now commonly occurs across much of SEA [4, 5]. Unlike the other dominant 
species causing human malaria, P. falciparum, some sporozoites (called bradysporozoites) 
of P. vivax develop into dormant forms in the liver called hypnozoites. This single feature—
latency—defines and distinguishes the prevention, treatment, and control of vivax malaria. 
Other sporozoites (called tachysporozoites) immediately develop into actively dividing 
hepatic schizonts over the 7-day to 18-day incubation period and cause the primary parasit-
emia and acute attack of patent vivax malaria. Hypnozoites activate weeks, months, or even 
years later, causing a renewed clinical attack called relapses [6].
In natural endemic settings, it may not be known if any given patient presenting with patent 
acute vivax malaria is experiencing a tachysporozoite-borne primary attack or a bradysporo-
zoite-borne relapse. This uncertainty poses a fundamental problem of interpretation of para-
sitemia that may follow therapy [5–8]. The origin of the parasitemia may be a consequence of 
new primary attack (reinfection), therapeutic failure against blood stages (recrudescence), or 
renewed latent malaria (relapse). These ambiguities may not be addressed by molecular geno-
typing techniques because relapses may be either homologous or heterologous to the primary 
infection event [9, 10]. Estimating the efficacy of blood schizonticidal therapy may thus be 
complex and difficult [11].
Another drug, a hypnozoitocide, is necessary to treat latent vivax malaria and prevent future 
attacks. Primaquine (PQ) has been the only available therapeutic option to kill hypnozoites 
since 1952. A single dose of 30 mg PQ within 48 hours of infection appears sufficient to kill 
stages of P. vivax or P. falciparum attempting to develop into hepatic schizonts or hypnozo-
ites [12]. Beyond that period, presumably after formation of dormant hypnozoites, relatively 
large doses totaling 210 to 420 mg of PQ (delivered over 7 to 56 days) are required to prevent 
Figure 1. Distribution of Plasmodium vivax malaria in the world.
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relapse [13]. Pharmacokinetic or pharmacodynamic interaction of blood schizonticidal and 
hypnozoitocidal therapies combined for the radical cure of vivax malaria has been observed 
and requires consideration in assessing the safety and efficacy of either or both in clinical 
use [14].
This chapter reviews the challenges vivax malaria poses in efforts to control and eliminate malaria 
in accordance with the Global Technical Strategy of the WHO [15] as they occur in many parts of 
the world. Experts advising the WHO formulated “Plasmodium vivax Control and Elimination: 
A Technical Brief” [16] highlighted the distinct character of this species in the context of control 
and elimination strategy. Conventional control aimed at diagnosing and treating of the acute 
attack and minimizing exposure to biting Anopheles mosquitoes will not suffice, largely due to 
the scale and importance of the latent hypnozoite reservoir in endemic communities. Decades 
of scientific, clinical, and public health neglect of this specific feature of vivax malaria leaves us 
poorly equipped to attack it safely and effectively. The biological basis of this problem is detailed 
with the aim of guiding discovery and development of sustainable solutions.
2. Biology of Plasmodium vivax
The broad and prolonged neglect of research on P. vivax has been highlighted by many 
researchers [17–20]. Although this lack of research certainly derives from complex and mul-
tiple factors, the misperception of this species as intrinsically benign perhaps dominates 
among them [21]. Today, we accept that a diagnosis of vivax malaria is sometimes associ-
ated with severe disease syndromes associated with fatal outcomes [16, 22]. The manner 
in which P. vivax threatens life with such typically low-grade parasitemias (usually tenfold 
lower than P. falciparum) is an important and relatively new question. Nonetheless, some 
researchers suggest that vivax malaria may be primarily an infection of hematopoietic tissues 
rather than of the vascular sinuses per se [21, 23, 24]. If most P. vivax biomass in the human 
host resides within tissues of the bone marrow and spleen, it would have far-reaching scien-
tific, clinical, and public health implications with respect to measuring and combatting the 
threats imposed.
We already know the likely importance of the latent hypnozoite reservoir and sub-patent/
asymptomatic parasitemias [25–27]. Adding an as-yet unacknowledged sequestered tro-
phozoite reservoir—very few or no asexual parasites in vascular sinuses but many in the 
extravascular spaces of erythropoietic tissues—would greatly amplify concerns regarding the 
effectiveness of diagnosis and treatment in control and elimination. It is possible that most 
P. vivax parasites—certainly hypnozoites but perhaps also trophozoites—occur beyond the 
vascular sinuses in both asymptomatic and acutely ill patients and, therefore, also beyond the 
reach of standard diagnostics.
Although the Duffy antigen on the surface of the red blood cell has long been considered 
essential to P. vivax invasion—and its absence in many African populations thought to explain 
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the relative rarity of P. vivax on that continent—recent evidence from a variety of African 
locales has shown patent P. vivax parasitemia in patients who are negative for that molecule 
[28]. Moreover, P. vivax has been shown to be present in parts of Africa where it is not preva-
lent [29] and is indeed prevalent in other areas of that continent like Madagascar, the Horn, 
and across the northern Sahel [30].
3. Chloroquine-resistant acute P. vivax
Resistance to CQ by the asexual stages of P. vivax has been documented in most endemic 
regions [4, 5]. Resistant strains dominate the malarious Western Pacific and Indonesian archi-
pelago and nations there have adopted highly efficacious ACTs [11] as first-line therapy. With 
the possible exception of artesunate combined with sulfadoxine-pyrimethamine, all ACTs 
have shown superb efficacy in killing asexual blood stages of P. vivax [31]. The safety and 
efficacy of PQ against relapse when combined with partner blood schizonticides other than 
CQ, quinine, or dihydroartemisinin-piperaquine [32, 33] require validation in clinical trials 
[14]. Elsewhere, for now, resistance appears sporadically and at relatively low frequencies. 
Despite substantial efforts to identify molecular markers of P. vivax resistance to antimalarial 
drugs, none have yet been validated. In vivo testing in patients or relatively difficult ex vivo 
drug testing procedures remain necessary [34]. The monitoring of antimalarial efficacy offers 
possible relief from risk of failure due to parasite resistance to specific therapies, but this is 
carried out relatively infrequently.
4. Latent and sub-patent P. vivax
The latent and sub-patent parasitemia caused by P. vivax is difficult or impractical to detect 
using available technologies. These unnoticed or invisible infections probably represent a 
dominant majority in most endemic settings. Thus, the primary blow to therapeutic effec-
tiveness (the proportion of patients needing a particular therapy and receiving high-quality 
drug in a full and adequately absorbed dose) is simply the inability to identify those in need 
of therapy.
The human host also imposes important barriers to the effectiveness of antimalarial therapies 
in the real world. Clinical contraindications, patient adherence, provider prescribing practices, 
provider and patient access to the drug, and its quality and availability; all further chip away the 
realizable effectiveness of any given antimalarial agent. The contraindications are particularly 
important in the case of P. vivax and the crucial therapy against relapses with PQ, the only cur-
rent therapeutic option for that clinical indication. Primaquine (and all other 8-aminoquinoline 
compounds evaluated) invariably provokes an acute hemolytic anemia in patients receiving 
therapeutic doses against relapse and having an inherited X chromosome-linked deficiency in 
glucose-6-phosphate dehydrogenase (G6PD) enzymatic activity [35]. This abnormality affects 
approximately 400 million people or 8% of people residing in malaria endemic countries [36]. 
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Safe access to PQ for radical cure of vivax malaria may require access to point-of-care diagnos-
tics for G6PD deficiency [37]. Even with such testing, however, there remains the problem of 
treating those diagnosed as G6PD-deficient, pregnant or lactating women, and infants below 
the age of 6 months [38]. There are no optimized or validated means of preventing relapse 
without 8-aminoquinoline drugs, e.g., by chemopreventive or presumptive periodic preventive 
therapeutic strategies [39, 40]. The 8-aminoquinoline drug, called tafenoquine, is in late clinical 
development and will likely soon offer a single-dose option to PQ, virtually eliminating the 
important adherence problem with that therapy [41, 42].
Another potential problem in the human host may be the inability to metabolize PQ to 
its active hypnozoite-killing metabolite by cytochrome P450 2D6 (CYP2D6) [43]. Natural 
polymorphism in the gene expressing CYP2D6 leads to a range of metabolic activities 
ranging anywhere between far above normal and null. Patients in need of PQ anti-relapse 
therapy and having significantly impaired or null CYP2D6 activity may relapse even with 
full compliance to good quality drug. We do not yet know the extent of this problem with 
regard to the frequencies of CYP2D6 alleles associated with PQ therapeutic failure, but the 
significantly impaired CYP2D6 *10 allele (a particular genetic variant of CYP2D6 gene) is 
relatively common among Southeast Asians, at about 35% frequency [44]. It may be that 
many Asians will be unable to adequately metabolize PQ and achieve successful radical 
cure [45].
The ambiguity of geographically variable frequency and timing of relapse—along with rein-
fection and recrudescence in recurrent P. vivax malaria after PQ therapy—makes estimat-
ing PQ efficacy in endemic settings very difficult. This is true even with directly observed 
therapy using high-quality drug. After decades of recommending a 5-day regimen of PQ 
against relapse, on the basis of observed low rates of relapse following therapy, investigators 
in India ultimately included a relapse control group (placebo) and discovered that efficacy 
to be nil [46]—the low rate of relapse was naturally occurring. John et al. [47] systematically 
reviewed recurrence rates after standard 0.25 mg/kg daily for 14-day regimen with rates of 
recurrence averaging about 8% at 1 month, 10% at 2–3 months, 14% at 4–6 months, and 20% at 
7–12 months. In two randomized controlled trials of PQ given at high dose (0.5 mg/kg) to 257 
Indonesian soldiers infected by P. vivax in eastern Indonesia and followed for a year where 
reinfection was not possible, 35 (14%) experienced at least one relapse [32, 33]. Among the 
21 subjects whose CYP2D6 genotype and phenotype were examined, 20 showed evidence of 
significant functional impairment of CYP2D6 [48].
Evidence supports the notion of providing presumptive anti-relapse therapy to all patients 
diagnosed with any species of malaria agents, especially P. falciparum. In a retrospective 
analysis of over 10,000 research subjects naturally infected by P. falciparum in Thailand or 
Myanmar, 912 were treated with rapidly excreted blood schizonticides, and within 2 months, 
just over 50% experienced a P. vivax attack [49]. The people infected by one species in any 
given community must be considered at high risk of harboring latent and perhaps sub-pat-
ent infections of the other co-endemic species. Species-specific therapies, especially in an 
age of dominant CQ resistance among the plasmodia, may not be sensible in an elimination 
context.
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Effective diagnosis and treatment represents the cornerstone of current control and elimi-
nation strategies, and the obstacles described here require consideration in realizing gains 
against this tenacious endemic problem. Indeed, such gains have been achieved both his-
torically and recently. At the turn of the twentieth century, endemic vivax malaria occurred 
across much of southeastern North America, northern and southern Europe, the Middle East, 
and northern Australia—areas where it no longer appears. Much of this success was achieved 
applying environmental modifications against local Anopheles vectors, but more recent elimi-
nation successes using principally diagnosis and treatment strategy have occurred in nations 
like Turkey, Azerbaijan, and Sri Lanka, as examples [50]. The same had been achieved on 
the Korean Peninsula during the 1970s, but endemic vivax malaria transmission reappeared 
during the 1990s and persists today [51]. Post-elimination vigilance that includes not only 
diagnosis and treatment services but also vector control may be essential to protecting and 
sustaining the elimination of endemic vivax malaria [50].
5. Vector control in vivax malaria
Vector control of endemic vivax malaria may not have immediate impacts due to the 
hypnozoite reservoir contributing >80% of acute attacks of vivax malaria in low or high 
endemic settings [52, 53]. Success in reducing malaria incidence and local transmis-
sion to zero in a malaria endemic area, particularly where sympatric P. falciparum and 
P. vivax occur, may require greater sustainability of vector control measures. Vivax 
malaria transmission will outlast falciparum malaria, and reestablishment of local 
transmission may occur without imported cases, i.e., by local hypnozoites. Prevention 
of the seeding of new hypnozoites in liver cells by biting Anopheles mosquitoes obvi-
ously may contribute positively to the control and elimination of vivax malaria in the 
long term, but no randomized controlled trials yet affirm this. In one large cluster-ran-
domized trial in Myanmar, insecticide-treated bed netting (ITN) had no impact what-
soever on the risk of malaria [54], an outcome attributed to the dominant Anopheles 
vector, A. dirus s.s., feeding predominantly outdoors and early in evening or morning 
[55]. Relatively modest effects were reported from a similarly cluster-randomized trial in 
Vietnam, again attributed to mosquito behaviors unfavorable to control by this means [56]. 
The main Asian vector species tend to feed early in the evening and outdoors where they 
also rest [57], minimizing their exposure to household insecticides. In other studies of 
strategies for minimizing exposure to Anopheles, much greater impacts against falciparum 
malaria were demonstrated relative to those against vivax malaria [58–60].
Over the last decade, attempts of using spatial repellents (SRs) to minimize exposure to biting 
insects have shown some success in diverse settings [61]. Repellency is distinct from the kill-
ing action of insecticides in more than one way, i.e., no direct contact is required, and lacking 
lethality does not select for resistance. SRs are effective irrespective of indoor or late-night 
feeding and resting behavior like conventional netting or indoor spraying. SRs should be 
evaluated for added benefit in areas where traditional long-lasting insecticidal net (LLIN) or 
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indoor residual spraying (IRS) of insecticides interventions may not offer full protection or 
have reached their efficacy limits—especially in areas with residual transmission or in areas 
where elimination may be considered feasible. Control of disease in these areas will require 
new approaches, and possibly spatial repellency would be practical and effective [62, 63]. SRs 
may be useful as stand-alone tools of personal or household protection where other interven-
tions may not reach. Also, they may be combined with conventional interventions to augment 
their impacts.
Another vector control strategy for eliminating P. vivax in the Asian-Pacific region may be 
the method of environmental modification called “species sanitation.” This approach offers 
prevention independently of the myriad problems and challenges of diagnosis and treat-
ment or the limitations of insecticidal strategies. Species sanitation is simply sanitizing the 
environment against specific incriminated vector species by exploiting detailed knowledge 
of their bionomics (behavior and ecology) [64]. Malcolm Watson in British Malaya, along 
with Nicholas Swellengrebel and Raden Soesilo in the East Indies, invented, optimized, and 
validated species sanitation in malaria control [65]. A systematic analysis of 16 such inter-
ventions (most conducted before 1945) showed an average 88% reduction of malaria bur-
den [66]. As new cases occur by relapse, reinfection, or importation, making the subsequent 
infection of mosquitoes improbable (by simply reducing their numbers) eventually suffocates 
transmission.
Although the implementation of LLIN, IRS, and species sanitation in different environmen-
tal settings rendered significant success rates [67], it is evident that the key determining fac-
tors for the success of any vector intervention selected is a thorough knowledge of the vector 
bionomics, local malaria transmission dynamics, and residual efficacy of choice insecticide. 
Knowledge of vector bionomics includes ascertaining breeding and resting preferences and 
feeding behavior of incriminated vector species. Transmission dynamics include informa-
tion related to entomological inoculation rates, sibling species composition of vectors (based 
on reliable PCR identification assays), seasonality of malaria prevalence, and risk factors 
that may support the human-mosquito contact, while suitable insecticide means any avail-
able insecticide that renders knockdown effect and/or mortality to the incriminated vector 
population.
Another important issue to be considered is the ability of the Anopheles mosquitoes to 
adapt to the ongoing vector interventions by changing host-seeking behavior, such as from 
indoor to outdoor or vice versa, and selection of insecticide-resistant strain [68]. With cur-
rent trends in globalization and population migration, deforestation, and resettlement of 
populations, reintroduction of malaria into areas that have been declared free from trans-
mission is a clear and present risk. Therefore, no single intervention method may guarantee 
long-term efficacy; thus, regular monitoring of vector density and behavior should be a 
routine operation wherever this risk occurs. Most malaria control programs no longer have 
the entomological expertise needed to carry out these important tasks—addressing this 
problem may be the greatest and most important challenge within the context of a malaria 
elimination agenda.
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6. Vaccination
A vaccine that prevents the seeding of human livers by both active schizonts and dormant 
hypnozoites of P. vivax would provide a conspicuously useful tool in eliminating this spe-
cies. Mass or routine vaccination now seems impractical with non-sterilizing vaccines of 
short-lived immunity needing 3 or 4 doses. These may improve in the future, but even now 
a malaria vaccine could be applied in geographically or demographically narrowed set-
tings to potentially great impacts. For example, high-risk and hard-to-reach populations like 
migrant workers or soldiers having sterile immunity to malaria (even if for just a season 
or two) may not only protect those people from harm but also greatly slow importation 
of malaria into receptive areas where transmission has been interrupted. Likewise, people 
living in areas prone to reintroduction of endemic malaria by high volumes of immigration 
from high-risk areas may be immunized and protected against very dangerous outbreaks 
and epidemics [69].
Today, there is no vaccine available that can prevent infection by P. vivax with high levels 
of sterilizing immune protection. That is also true for all other plasmodial species. The 
half-century-long efforts to develop a vaccine against P. falciparum—greatly aided by the 
ability to cultivate this species in continuous laboratory cultures since the late 1970s—
culminated in the molecular subunit vaccine called RTS,S ASO1 (mimicking a protein-
coating infectious sporozoites) [70] with the registered trademark name Mosquirix™ 
(GlaxoSmithKline). The vaccine did not prevent infection in the African infants and young 
children vaccinated but had the modest effects against higher parasitemias and signs of ill-
ness [67]. The modest efficacy combined with worrying and puzzling signals like increased 
risk of pneumococcal meningitis and significantly higher all-cause mortality among vac-
cinated females apparently explains the WHO position to withhold a favorable opinion on 
the vaccine until further studies involving targeted and limited rollout in several African 
nations are completed [71]. Molecular subunit vaccines targeting P. vivax molecules have 
not progressed beyond Phase 2a and show similar inability to achieve high levels of steril-
izing protection [72].
Over the past decade, investigators applying live-attenuated sporozoites of P. falciparum have 
shown high levels of durable (~12 months) sterilizing protection in malaria-naïve adult vol-
unteers in controlled human malaria infection (CHMI) experiments using a challenge strain 
homologous to the vaccine strain [73]. This approach relies on laboratory harvest of infectious 
sporozoites from laboratory-reared aseptic anopheline mosquitoes infected by P. falciparum 
maintained in the laboratory. Deriving live-attenuated sporozoites of P. vivax is possible 
[74] but exceedingly difficult, not strain-specific, and not sustainable as a source of vaccine. 
Nonetheless, immunization by irradiated sporozoites of the murine species Plasmodium ber-
ghei cross-protected against the murine species Plasmodium yoelii and vice versa in murine chal-
lenge models [75]. The possibility of sporozoites of P. falciparum cross-protecting against P. 
vivax challenge has not been examined directly, but proteomic analyses showed that these 
two human plasmodia species shared substantially more common probable T-cell epitopes 
than that between P. berghei and P. yoelii. A vaccine derived from laboratory-kept P. falciparum 
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systems offering protection against P. vivax would represent a quantum leap forward for vac-
cination against this species by effectively sidestepping the requirement for continuous labo-
ratory cultivation for a live vaccine.
7. Challenges and recommendations
The greatest challenge in eliminating vivax malaria—the hypnozoite reservoir—may also 
be the greatest opportunity to accomplish the task. If >80% of incident malaria cases indeed 
derive from hypnozoites, then surely attacking and shrinking that reservoir would deliver 
substantial reductions in the burden of morbidity and mortality. Despite the availability of 
PQ for over 65 years, sustained and systematic assault on that reservoir has not been accom-
plished in the endemic tropics—largely due to the unsolved clinical problem of its hemolytic 
toxicity in G6PD-deficient patients.
Eliminating P. vivax malaria will require accepting the inadequacy of conventional falciparum 
malaria-focused control strategy, tactics, and tools and committing to the optimizing and vali-
dating of interventions suited to this stubborn parasite. This effectively means striving to 
solve the wrenchingly difficult problem of the hemolytic toxicity of PQ in G6PD-deficient 
patients by almost any means. The obstacles presented in managing populations and individ-
ual patients carrying this infection emphasize the great advantage of preventing it in the first 
place with an effective vector control strategy. In this context, species sanitation has proven 
highly effective against endemic Asian malarias a century ago [54] and would probably do 
so again.
Taking all these factors into considerations, we recommend the following measures for elimi-
nating endemic vivax malaria:
1. Active case detection and early treatment are essential steps, fundamental to eliminating 
any endemic malaria; however, this measure alone will not lead to elimination—too many 
infections are latent, sub-patent, sequestered, and asymptomatic.
2. Adoption of safe and universal access to radical cure for cases of vivax malaria along with 
universal access to alternative means of relapse prevention for people ineligible for thera-
py with 8-aminoquinolines would accelerate progress to elimination. Achieving that will 
likely also require better diagnostics for both the parasite and G6PD deficiency than are 
currently available.
3. Adoption of radical cure with an 8-aminoquinoline and ACT with diagnosis of any species 
of malaria where P. vivax also occurs as a means of targeting likely carriers of hypnozoites.
4. Reduce new vivax infections/seeding of the liver with hypnozoites by substantially re-
ducing human contact with malaria vectors, effectively stranding extant parasites in all 
stages of human infection—latent, sub-patent, patent, and eventually vanishing without 
Anopheles contact and onward transmission. Interrupting transmission by species sanita-
tion measures may be the most durable and effective means of achieving this goal.
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5. Examine the possibility of sterilizing immune protection against P. vivax provided by at-
tenuated P. falciparum sporozoite vaccines providing an immediately highly relevant tool 
for eliminating endemic P. vivax.
8. Conclusion
Plasmodium vivax passes substantial challenges that may hinder achievement of global malaria 
elimination by 2030. The most challenging evidence is the lack of technology to detect the 
latent infection caused by hypnozoite. Therefore, the only tool to prevent P. vivax transmis-
sion originated from reactivation of hypnozoites is by vector control.
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